Spyridon Papapetropoulos Form 3 Vigil Neuroscience / Spyridon Papapetropoulos ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Papapetropoulos Spyridon

(Last) (First) (Middle)

VIGIL NEUROSCIENCE, INC.

1 BROADWAY, 7TH FLOOR, SUITE 07-300

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/06/2022

3. Issuer Name and Ticker or Trading Symbol
Vigil Neuroscience, Inc. [ VIGL ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option Grant (Right to Buy)	(1)	11/18/2030	Common Stock	149,904	1.89	D
Stock Option Grant (Right to Buy)	(2)	06/03/2031	Common Stock	62,459	3.78	D
Stock Option Grant (Right to Buy)	(3)	08/18/2031	Common Stock	59,006	6.02	D
Stock Option Grant (Right to Buy)	(4)	10/13/2031	Common Stock	21,635	9.57	D

Explanation of Responses:

1. 25% of the shares subject to this option vested and became exercisable on September 14, 2021, with the remainder vesting in 36 equal monthly installments thereafter.

2. 25% of the shares subject to this option shall vest and become exercisable on June 1, 2022, with the remainder vesting in 36 equal monthly installments thereafter.

3. The shares subject to this option vest and become exercisable in 48 equal monthly installments, with the first installment vested September 13, 2021.

4. The shares subject to this option vest and become exercisable in 48 equal monthly installments, with the first installment vested November 14, 2021.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jennifer Ziolkowski, Attorney-in-Fact	01/06/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.